G. Gross

3.9k total citations · 2 hit papers
15 papers, 2.9k citations indexed

About

G. Gross is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, G. Gross has authored 15 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Immunology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in G. Gross's work include CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Immune Cell Function and Interaction (5 papers). G. Gross is often cited by papers focused on CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Immune Cell Function and Interaction (5 papers). G. Gross collaborates with scholars based in Israel, United States and Germany. G. Gross's co-authors include Zelig Eshhar, Tova Waks, Daniel Schindler, Guy Gorochov, R Cowherd, Patrick Hwu, GE Shafer, Steven A. Rosenberg, Jonathan Treisman and Mia Horowitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The EMBO Journal.

In The Last Decade

G. Gross

15 papers receiving 2.8k citations

Hit Papers

Specific activation and targeting of cytotoxic lymphocyte... 1989 2026 2001 2013 1993 1989 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Gross Israel 11 2.6k 1.3k 836 792 743 15 2.9k
Mathilde Poussin United States 24 2.1k 0.8× 1.1k 0.9× 595 0.7× 679 0.9× 767 1.0× 41 2.8k
Tova Waks Israel 26 3.7k 1.4× 2.1k 1.7× 1.2k 1.4× 1.2k 1.5× 1.0k 1.4× 54 4.5k
Mio Kitano United States 11 1.9k 0.7× 797 0.6× 600 0.7× 599 0.8× 646 0.9× 21 2.4k
Carolina Berger United States 28 3.0k 1.2× 1.5k 1.2× 1.1k 1.4× 1.2k 1.6× 782 1.1× 49 3.9k
Catherine Lindgren United States 19 2.5k 1.0× 1.1k 0.9× 801 1.0× 691 0.9× 643 0.9× 40 2.9k
Sarwish Rafiq United States 15 2.2k 0.8× 1.1k 0.9× 537 0.6× 916 1.2× 767 1.0× 34 2.8k
Markus Chmielewski Germany 30 3.5k 1.3× 1.7k 1.3× 1.0k 1.3× 1.1k 1.4× 1.2k 1.6× 38 4.0k
Daniel Sommermeyer United States 25 3.4k 1.3× 1.5k 1.2× 1.1k 1.3× 1.2k 1.5× 1.1k 1.5× 39 3.8k
Terence J. Purdon United States 22 2.9k 1.1× 1.1k 0.9× 837 1.0× 963 1.2× 1.0k 1.3× 41 3.1k
Eric Yvon United States 28 2.6k 1.0× 1.8k 1.5× 867 1.0× 900 1.1× 698 0.9× 49 3.6k

Countries citing papers authored by G. Gross

Since Specialization
Citations

This map shows the geographic impact of G. Gross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Gross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Gross more than expected).

Fields of papers citing papers by G. Gross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Gross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Gross. The network helps show where G. Gross may publish in the future.

Co-authorship network of co-authors of G. Gross

This figure shows the co-authorship network connecting the top 25 collaborators of G. Gross. A scholar is included among the top collaborators of G. Gross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Gross. G. Gross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Eisenberg, Galit, Arthur Machlenkin, Alon Margalit, et al.. (2015). Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clinical & Experimental Immunology. 182(2). 220–229. 15 indexed citations
2.
Cafri, Gal, Gabriela Koifman, Sigal Fishman, et al.. (2011). Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. International Immunology. 23(7). 453–461. 11 indexed citations
3.
Gross, G. & Alon Margalit. (2007). Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway. Endocrine Metabolic & Immune Disorders - Drug Targets. 7(2). 99–109. 12 indexed citations
4.
Busse, W., et al.. (2006). Phase 2/3 Study of the Novel Vaccine Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate AIC in Ragweed-Allergic Adults. Journal of Allergy and Clinical Immunology. 117(2). S88–S89. 10 indexed citations
5.
Gross, G., Shoshana Levy, Ronald Levy, Tova Waks, & Zelig Eshhar. (1995). Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochemical Society Transactions. 23(4). 1079–1082. 16 indexed citations
6.
Hwu, Patrick, GE Shafer, Jonathan Treisman, et al.. (1993). Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.. The Journal of Experimental Medicine. 178(1). 361–366. 207 indexed citations
7.
Eshhar, Zelig, G. Gross, & Jonathan Treisman. (1993). Modifying the specificity of T cells using chimeric Ig/TCR genes. 1 indexed citations
8.
Gorochov, Guy, G. Gross, Tova Waks, & Zelig Eshhar. (1993). Anti-leucocyte function-associated antigen-1 antibodies inhibit T-cell activation following low-avidity and adhesion-independent interactions.. PubMed. 79(4). 548–55. 5 indexed citations
9.
Eshhar, Zelig, Tova Waks, G. Gross, & Daniel Schindler. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.. Proceedings of the National Academy of Sciences. 90(2). 720–724. 1248 indexed citations breakdown →
10.
Gorochov, Guy, et al.. (1992). Functional assembly of chimeric T-cell receptor chains.. PubMed. 7. 53–7. 5 indexed citations
11.
Eshhar, Zelig & G. Gross. (1990). Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach.. PubMed. 10. 27–9. 19 indexed citations
12.
Gross, G., Guy Gorochov, Tova Waks, & Zelig Eshhar. (1989). Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity.. PubMed. 21(1 Pt 1). 127–30. 117 indexed citations
13.
Gross, G., Tova Waks, & Zelig Eshhar. (1989). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.. Proceedings of the National Academy of Sciences. 86(24). 10024–10028. 1169 indexed citations breakdown →
14.
Gross, G., et al.. (1987). Promoter and enhancer elements in the rearranged alpha chain gene of the human T cell receptor.. The EMBO Journal. 6(11). 3307–3312. 47 indexed citations
15.
Doerr, Hans Wilhelm, G. Gross, Herbert Schmitz, & Gisela Enders. (1976). Neutralizing serum IgM antibodies in infections withHerpes simplex virus hominis. Medical Microbiology and Immunology. 162(3-4). 183–192. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026